Molecules with altered neonate Fc receptor binding having enhanced therapeutic and diagnostic properties
US11767369B2 · kind B2 · utility
0Cited by
2References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 10, 2019 |
| Grant date | Sep 26, 2023 |
| Priority date | — |
| Expiry date | Jul 6, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fc region) (e.g., from a human IgG, e.g., human IgG1), that have modifications of one or more of amino acid residues in at least the CH3 domain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.